Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Debt Repayments (2021 - 2024)

Historic Long-Term Debt Repayments for Seres Therapeutics (MCRB) over the last 5 years, with Q3 2024 value amounting to $127.9 million.

  • Seres Therapeutics' Long-Term Debt Repayments changed N/A to $127.9 million in Q3 2024 from the same period last year, while for Dec 2024 it was $127.9 million, marking a year-over-year increase of 14196.94%. This contributed to the annual value of $127.9 million for FY2024, which is 14196.94% up from last year.
  • Seres Therapeutics' Long-Term Debt Repayments amounted to $127.9 million in Q3 2024.
  • Over the past 5 years, Seres Therapeutics' Long-Term Debt Repayments peaked at $127.9 million during Q3 2024, and registered a low of $948000.0 during Q4 2021.
  • For the 4-year period, Seres Therapeutics' Long-Term Debt Repayments averaged around $45.9 million, with its median value being $27.4 million (2022).